⚠ COVID-19 INFORMATION: Resources, Vaccine Information

A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin

Official Title: A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin

The primary objective of this study is to evaluate the efficacy of moxetumomab pasudotox in pediatric subjects with relapsed or refractory B-cell ALL or B-cell lymphoblastic lymphoma

ClinicalTrials.gov ID: NCT02227108

Principal Investigator: Hijiya, Nobuko, MD

Study Type: Interventional

Currently Recruiting Patients: No

Contact Information:

Nobuko Hijiya, MD

Principal Investigator

312.227.4090